Drugs / CUE-102
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06917885 | Jul 2025 → Jan 2027 expected | glioblastoma | David Reardon, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT05360680 | Jun 2022 → Mar 2025 | colorectal cancer, gastric cancer, malignant pancreatic neoplasm, ovarian cancer | Cue Biopharma | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-05-12 | LG Life Sciences | Regulatory LG Chem’s 4th anti-cancer milestone enters Phase I clinical trial in the US lgchem.com ↗
On the 12th, LG Chem announced that its American counterpart Cue Biopharma received FDA acceptance of IND application for CUE-102 and cleared to proceed with its Phase I clinical trial plans. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-05-12 | LG Life Sciences | LG Chem’s 4th anti-cancer milestone enters Phase I clinical trial in the US lgchem.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CUE-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06917885 ↗ |
| Action | Activate | “CUE-102 is designed to target tumor cells by activating T cells” NCT06917885 ↗ |
| Modality | Protein / enzyme biologic | “CUE-102 is a novel fusion protein” NCT05360680 ↗ |
| Route | Intravenous | “CUE-102 intravenous (IV) monotherapy” NCT05360680 ↗ |